Biotech startups in Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Adaptyv Biosystems | Lausanne | Series A | $40.0M | 2026-08-25 |
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Alithea Genomics | Lausanne | Seed | $3.8M | 2026-03-04 |
| GlycoEra | Wädenswil | Series B | $130.0M | 2025-05-27 |
| Cutiss | Zürich | Series C | $38.8M | 2025-09-10 |
| Memo Therapeutics | Schlieren | Series C | $22.0M | 2024-05-07 |
| NovaGo Therapeutics | Schlieren | Series B | $29.7M | 2026-08-31 |
8 rows of the CSV in 5 of its 18 columns.
- The 207 biotech startups in Switzerland have raised $4.2B in total.
- 24 of them closed their most recent round in the last 12 months, $659.3M combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is Vale Biolabs' $183K seed round on 9 November 2026.
- Venture Kick is an investor in 45 of them, more than any other fund.
- Health care is the most common other sector, with 171 companies (83%).
- 27% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 1 to 10 employees (52% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 207| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Alithea Genomics | Alithea Genomics develops molecular biology tools and sequencing solutions for large-scale gene expression analysis. | Biotech | Lausanne | Seed | $3.8M | 2026-03-04 | $9.9M | Foundation for Innovation and Technology (FIT), TechU Ventures, Eurostars +1 | 11 to 50 | 2020 |
| Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| FluoSphera | FluoSphera develops drugs. | Biotech | Geneva | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| Genknowme | Genknowme is a precision health company advancing epigenetics to support personalized and preventive care. | Biotech | Lausanne | Pre-seed | $630K | 2025-12-18 | $947K | Venture Kick, Foundation for Innovation and Technology (FIT) | 1 to 10 | 2019 |
| Hemostod | HemostOD manufactures platelets on demand from engineered stem cells. | Biotech | Lausanne | Seed | $5.4M | 2025-10-01 | $7.8M | Foundation for Innovation and Technology (FIT) | 11 to 50 | 2020 |
| Cutiss | Cutiss is a life science company that produces regenerative medicine and engineers skin tissue. | Biotech | Zürich | Series C | $38.8M | 2025-09-10 | $94.6M | Innosuisse | 11 to 50 | 2017 |
| Comphya | Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. | Biotech | Lausanne | Series A | $4.0M | 2025-07-08 | $14.2M | Venture Kick, Verve Ventures, Nest Collective Foundation | 1 to 10 | 2017 |
| Adiposs | Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. | Biotech | Geneva | Series A | $5.0M | 2025-06-30 | $7.4M | MassChallenge, Venture Kick, FONGIT Innovation Fund +2 | 1 to 10 | 2020 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| CellX Biosolutions | CellX Biosolutions provides sustainable treatment of chemical waste. | Biotech | Zürich | Pre-seed | $1.9M | 2025-02-25 | $2.1M | Venture Kick, MassChallenge Switzerland | 1 to 10 | 2024 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Alentis Therapeutics | Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. | Biotech | Allschwil | Series D | $181.4M | 2024-11-12 | Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 | 51 to 100 | 2019 | |
| Translation-X | Translation-X is a spin-off project developing novel therapeutics for autism spectrum disorders. | Biotech | Basel | Pre-seed | $177K | 2024-09-30 | Venture Kick | 1 to 10 | 2022 | |
| ImmunOs Therapeutics | ImmunOs Therapeutics is a clinical-stage biotechnology company. | Biotech | Schlieren | Series C | $11.0M | 2024-09-17 | Lightspeed Venture Partners, Innosuisse, Mission BioCapital +1 | 11 to 50 | 2014 | |
| Abrinca Genomics | Abrinca Genomics is a biotechnology company. | Biotech | Bern | Seed | $178K | 2024-09-16 | Venture Kick | 1 to 10 | 2023 | |
| CorFlow Therapeutics | CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. | Biotech | Baar | Series B | $48.5M | 2024-09-10 | $66.1M | Innosuisse, Unorthodox Ventures, Panakes Partners +2 | 11 to 50 | 2016 |
| Regenosca | Regenosca develops biomaterials that serve as alternatives to autologous tissue substitutes for soft tissue repair. | Biotech | Lausanne | Pre-seed | $1.1M | 2024-07-22 | $1.4M | MassChallenge, Venture Kick, Foundation for Innovation and Technology (FIT) +1 | 1 to 10 | 2019 |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| iOnctura | iOnctura is a clinical-stage biotechnology company developing treatments for cancer. | Biotech | Geneva | Series B | $85.7M | 2024-06-20 | European Innovation Council, M Ventures, VI Partners +2 | 11 to 50 | 2017 | |
| NXI Therapeutics | NXI Therapeutics develops immunosuppressive drugs for autoimmune diseases and organ transplantation. | Biotech | Basel | Pre-seed | $4.0M | 2024-06-18 | $4.0M | Venture Kick, Kickfund, Gebert Rüf Stiftung +1 | 1 to 10 | 2021 |
| Memo Therapeutics | Memo Therapeutics conducts biotechnology research in antibody discovery and immune repertoire analysis. | Biotech | Schlieren | Series C | $22.0M | 2024-05-07 | $108.8M | Verve Ventures, Kurma Partners, Pureos Bioventures +1 | 11 to 50 | 2012 |
| Neurosterix | Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. | Biotech | Geneva | Series A | $65.0M | 2024-04-03 | $65.0M | Perceptive Advisors, Xontogeny, Acorn Bioventures | 11 to 50 | 2024 |
| Hemotune | Hemotune develops a therapeutic blood purification platform for treating health conditions. | Biotech | Schlieren | Series B | $15.6M | 2024-03-25 | Venture Kick, Innosuisse, Gebert Rüf Stiftung | 11 to 50 | 2016 | |
| Myria Biosciences | Myria Biosciences discovers natural product drugs using genetically engineered cells that produce them. | Biotech | Basel | Pre-seed | $1.9M | 2024-01-05 | $1.9M | Creator Fund | 1 to 10 | 2022 |
Table 1. Biotech startups in Switzerland: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 207.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 3 | FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel | Series A | $50.0M | 2025-12-18 | $109.4M | EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 | 11 to 50 | 2019 |
| 4 | Adaptyv Biosystems | Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. | Artificial intelligence | Lausanne | Series A | $40.0M | 2026-08-25 | $50.9M | Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 | 11 to 50 | 2020 |
| 5 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| 6 | Leman Biotech | Leman Biotech develops cancer immunotherapies as a biotech company. | Biotech | Lausanne | Series A | $28.8M | 2026-01-26 | $46.8M | Tiantu Capital, Fuho Capital | 11 to 50 | 2021 |
| 7 | Alithea Genomics | Alithea Genomics develops molecular biology tools and sequencing solutions for large-scale gene expression analysis. | Biotech | Lausanne | Seed | $3.8M | 2026-03-04 | $9.9M | Foundation for Innovation and Technology (FIT), TechU Ventures, Eurostars +1 | 11 to 50 | 2020 |
| 8 | FluoSphera | FluoSphera develops drugs. | Biotech | Geneva | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| 9 | Genknowme | Genknowme is a precision health company advancing epigenetics to support personalized and preventive care. | Biotech | Lausanne | Pre-seed | $630K | 2025-12-18 | $947K | Venture Kick, Foundation for Innovation and Technology (FIT) | 1 to 10 | 2019 |
Table 2. Biotech startups in Switzerland: the 9 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Venture Kick | Startup incubator | Schlieren, Switzerland | 45 | 22% | 2 | Adaptyv Biosystems, Genknowme |
| 2 | Foundation for Innovation and Technology (FIT) | Entrepreneurship program | Lausanne, Switzerland | 10 | 5% | 3 | Adaptyv Biosystems, Alithea Genomics, Genknowme |
| 3 | Innosuisse | Government investment office | Berne, Switzerland | 9 | 4% | ||
| 4 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 9 | 4% | 1 | FoRx Therapeutics |
| 5 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 7 | 3% | 1 | Windward Bio |
| 6 | BioMedPartners | Venture capital firm | Basel, Switzerland | 7 | 3% | ||
| 7 | MassChallenge | Startup accelerator | Boston, United States | 7 | 3% | ||
| 8 | VI Partners | Venture capital firm | Altendorf, Switzerland | 6 | 3% | ||
| 9 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 6 | 3% | 1 | FoRx Therapeutics |
| 10 | Versant Ventures | Venture capital firm | Menlo Park, United States | 6 | 3% | ||
| 11 | Verve Ventures | Venture capital firm | Zug, Switzerland | 5 | 2% | ||
| 12 | Omega Funds | Secondary purchaser | Boston, United States | 5 | 2% | 1 | FoRx Therapeutics |
| 13 | OrbiMed | Private equity firm | New York, United States | 4 | 2% | 1 | Windward Bio |
| 14 | Sofinnova Partners | Venture capital firm | Paris, France | 4 | 2% | ||
| 15 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 4 | 2% |
Table 3. Biotech startups in Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 171 | 83% | $3.9B |
| Software | 24 | 12% | $79.4M |
| Artificial intelligence | 12 | 6% | $66.7M |
| Hardware | 8 | 4% | $1.3M |
| Fintech | 3 | 1% | |
| Education | 2 | 1% | $3.6M |
| Commerce | 2 | 1% | $4.7M |
| Cybersecurity | 1 | 0% | $4.7M |
Table 4. Biotech startups in Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 4% | $183K |
| October 2026 | 2 | 8% | $139.5M |
| September 2026 | 2 | 8% | $5.4M |
| August 2026 | 3 | 12% | $221.7M |
| July 2026 | 1 | 4% | $2.8M |
| June 2026 | 2 | 8% | $124K |
| May 2026 | 1 | 4% | $165.0M |
| April 2026 | 3 | 12% | $21.0M |
| March 2026 | 1 | 4% | $3.8M |
| February 2026 | 1 | 4% | $873K |
| January 2026 | 4 | 17% | $42.7M |
| December 2025 | 3 | 12% | $56.3M |
Table 7. Biotech startups in Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 21 | 10% | $603.1M |
| 2025 | 25 | 12% | $564.6M |
| 2024 | 25 | 12% | $848.4M |
| 2023 | 15 | 7% | $167.1M |
| 2022 | 15 | 7% | $198.8M |
| 2021 | 17 | 8% | $110.1M |
Table 8. Biotech startups in Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 21 | 10% |
| 2020 to 2022 | 34 | 17% |
| 2015 to 2019 | 72 | 35% |
| 2010 to 2014 | 38 | 18% |
| Before 2010 | 41 | 20% |
Table 9. Biotech startups in Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 107 | 52% |
| 11 to 50 | 79 | 39% |
| 51 to 100 | 15 | 7% |
| 101 to 250 | 2 | 1% |
| 251 to 500 | 1 | 0% |
| 1,001 to 5,000 | 1 | 0% |
Table 10. Biotech startups in Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Switzerland. On 16 November 2026 that is 207 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 207 rows: 32 have no round amount, 0 no city and 78 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Switzerland are on the list?
- 207, in the file dated 16 November 2026. 24 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 207 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.